ScoreWhy is Lincoln Pharmaceuticals Ltd ?
1
The company is Net-Debt Free
2
Poor long term growth as Net Sales has grown by an annual rate of 9.42% and Operating profit at 0.87% over the last 5 years
3
Positive results in Jun 26
- DEBTORS TURNOVER RATIO(HY) Highest at 4.16 times
- PBDIT(Q) Highest at Rs 27.43 cr.
- PBT LESS OI(Q) Highest at Rs 23.29 cr.
4
With ROE of 11.6, it has a Attractive valuation with a 1.6 Price to Book Value
- The stock is trading at a fair value compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 13.62%, its profits have risen by 11.7% ; the PEG ratio of the company is 1.1
5
Falling Participation by Institutional Investors
- Institutional investors have decreased their stake by -1.41% over the previous quarter and collectively hold 4.87% of the company
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors
6
Market Beating Performance
- The stock has generated a return of 13.62% in the last 1 year, much higher than market (BSE500) returns of 1.95%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Lincoln Pharma. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Lincoln Pharma. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Lincoln Pharma.
13.45%
0.34
40.08%
Sensex
-4.88%
-0.36
13.50%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
9.42%
EBIT Growth (5y)
0.87%
EBIT to Interest (avg)
58.08
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.31
Sales to Capital Employed (avg)
0.97
Tax Ratio
24.53%
Dividend Payout Ratio
4.38%
Pledged Shares
0
Institutional Holding
4.87%
ROCE (avg)
21.16%
ROE (avg)
14.03%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
13
Industry P/E
37
Price to Book Value
1.63
EV to EBIT
11.59
EV to EBITDA
9.88
EV to Capital Employed
1.92
EV to Sales
1.44
PEG Ratio
1.10
Dividend Yield
0.29%
ROCE (Latest)
15.97%
ROE (Latest)
11.60%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
Bullish
Bearish
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend11What is working for the Company
DEBTORS TURNOVER RATIO(HY)
Highest at 4.16 times
PBDIT(Q)
Highest at Rs 27.43 cr.
PBT LESS OI(Q)
Highest at Rs 23.29 cr.
PAT(Q)
At Rs 36.23 cr has Grown at 30.9%
EPS(Q)
Highest at Rs 18.09
-3What is not working for the Company
ROCE(HY)
Lowest at 15.30%
NON-OPERATING INCOME(Q)
is 51.02 % of Profit Before Tax (PBT
Loading Valuation Snapshot...
Here's what is working for Lincoln Pharma.
Operating Profit (PBDIT) - Quarterly
Highest at Rs 27.43 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 23.29 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 36.23 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 36.23 cr has Grown at 30.9%
Year on Year (YoY)MOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 18.09
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Debtors Turnover Ratio- Half Yearly
Highest at 4.16 times
in the last five half yearly periodsMOJO Watch
Company has been able to settle its Debtors faster
Debtors Turnover Ratio
Here's what is not working for Lincoln Pharma.
Non Operating Income - Quarterly
is 51.02 % of Profit Before Tax (PBT)
MOJO Watch
The company's income from non business activities is high; which is not a sustainable business model
Non Operating Income to PBT
Non Operating Income - Quarterly
Highest at Rs 24.26 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
